FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	9,	 	

l	OMB APP	ROVAL
l	OMB Number:	3235-02

87 Estimated average burden

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or Sec	tion 30(n) (of the	Investment	Com	ipany Act	of 1940							
1. Name and Address of Reporting Person* <u>LaViscount Joyce N</u>				<u>H</u>	2. Issuer Name and Ticker or Trading Symbol HELIUS MEDICAL TECHNOLOGIES, INC. [HSDT]						(Che	S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) HELIUS MEDICAL TECHNOLOGIES, INC.						3. Date of Earliest Transaction (Month/Day/Year) 10/21/2015							X	Officer (give title below) CFO and C			Other (s below)	pecify
SUITE 400, 41 UNIVERSITY DRIVE					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable						
(Street) NEWTOWN PA 18940					10/23/2015							Line)	X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(S	tate)	(Zip)											Person				
		Та	ble I - Non-	Derivati	ve Se	ecurities	s Ac	quired, D	Disp	osed o	f, or B	enef	ficially	Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					2A. Deemed Execution Date, if any (Month/Day/Year		e, Transaction Disposed Code (Instr.		ities Acquired (A) o d Of (D) (Instr. 3, 4 a			Beneficial Owned Fo	Formula (D) (I) (I) (I) (I) (I)	Form: (D) or	orm: Direct 0) or Indirect 1 (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount (A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)				instr. 4)			
			Table II - D					uired, Di						Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transactions	e s ally	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	or Nu	nount mber Shares	nt er		on(a)	<u>'</u>	
Stock Option	\$0.67 ⁽¹⁾	10/21/2015		A		750,000		(2)	10	0/21/2020	Class A		50.000	\$0	750,00	00	D	

Explanation of Responses:

- 1. Translated into U.S. dollars from Canadian dollars based on the noon buying rate from the Federal Reserve Bank of USD\$1.00 = CAD\$1.2932 on October 16, 2015, based on an option exercise price of
- 2. Twenty-five percent of the shares subject to this option vested on the grant date. An additional 25% of the shares subject to this option will vest on each of October 21, 2016, October 21, 2017, and October 21, 2018.

Remarks:

Buy)

This amendment to Form 4 is being filed to correct the disclosure regarding the vesting dates of the shares subject to the option granted to the Reporting Person.

Charles Lee, Attorney-in-Fact 11/05/2015

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.